| [1] |
Nowbar AN, Gitto M, Howard JP, et al. Mortality from ischemic heart disease [J]. Circ Cardiovasc Qual Outcomes, 2019, 12(6): e005375. doi:10.1161/circoutcomes.118.005375
|
| [2] |
Cífková R. Gender differences in secondary prevention of coronary heart disease: far from closing the gap [J]. Int J Cardiol, 2022, 355: 52-3. doi:10.1016/j.ijcard.2022.03.003
|
| [3] |
Li J, Zheng L, Chan KHK, et al. Sex hormone-binding globulin and risk of coronary heart disease in men and women [J]. Clin Chem, 2023, 69(4): 374-85. doi:10.1093/clinchem/hvac209
|
| [4] |
Rosen SE, Henry S, Bond R, et al. Sex-specific disparities in risk factors for coronary heart disease [J]. Curr Atheroscler Rep, 2015, 17(8): 49. doi:10.1007/s11883-015-0523-8
|
| [5] |
Khoja A, Andraweera PH, Lassi ZS, et al. Risk factors for premature coronary heart disease in women compared to men: systematic review and meta-analysis [J]. J Womens Health (Larchmt), 2023, 32(9): 908-20. doi:10.1089/jwh.2022.0517
|
| [6] |
Kim HL, Kim MA. Sex differences in coronary artery disease: insights from the Korean women's chest pain registry (KoROSE) [J]. Korean Circ J, 2023, 53(10): 655-76. doi:10.4070/kcj.2023.0205
|
| [7] |
Mrdovic I, Savic L, Asanin M, et al. Sex-related analysis of short- and long-term clinical outcomes and bleeding among patients treated with primary percutaneous coronary intervention: an evaluation of the risk-PCI data [J]. Can J Cardiol, 2013, 29(9): 1097-103. doi:10.1016/j.cjca.2012.11.013
|
| [8] |
Heer T, Hochadel M, Schmidt K, et al. Sex differences in percutaneous coronary intervention-insights from the Coronary Angiography and PCI Registry of the German Society of Cardiology [J]. J Am Heart Assoc, 2017, 6(3): e004972. doi:10.1161/jaha.117.002331
|
| [9] |
Bai MF, Wang X. Risk factors associated with coronary heart disease in women: a systematic review [J]. Herz, 2020, 45(): 52-7. doi:10.1007/s00059-019-4835-2
|
| [10] |
Kim MS, Kim WJ, Khera AV, et al. Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies [J]. Eur Heart J, 2021, 42(34): 3388-403. doi:10.1093/eurheartj/ehab454
|
| [11] |
Vecchié A, Dallegri F, Carbone F, et al. Obesity phenotypes and their paradoxical association with cardiovascular diseases [J]. Eur J Intern Med, 2018, 48: 6-17. doi:10.1016/j.ejim.2017.10.020
|
| [12] |
Jia G, Jia Y, Sowers JR. Contribution of maladaptive adipose tissue expansion to development of cardiovascular disease [J]. Compr Physiol, 2016, 7(1): 253-62. doi:10.1002/j.2040-4603.2017.tb00743.x
|
| [13] |
Roos CJ, Quax PH, Jukema JW. Cardiovascular metabolic syndrome: mediators involved in the pathophysiology from obesity to coronary heart disease [J]. Biomark Med, 2012, 6(1): 35-52. doi:10.2217/bmm.11.105
|
| [14] |
Elagizi A, Kachur S, Lavie CJ, et al. An overview and update on obesity and the obesity paradox in cardiovascular diseases [J]. Prog Cardiovasc Dis, 2018, 61(2): 142-50. doi:10.1016/j.pcad.2018.07.003
|
| [15] |
Mongraw-Chaffin ML, Peters SAE, Huxley RR, et al. The sex-specific association between BMI and coronary heart disease: a systematic review and meta-analysis of 95 cohorts with 1.2 million participants [J]. Lancet Diabetes Endocrinol, 2015, 3(6): 437-49. doi:10.1016/s2213-8587(15)00086-8
|
| [16] |
Fan J, Song Y, Wang Y, et al. Dietary glycemic index, glycemic load, and risk of coronary heart disease, stroke, and stroke mortality: a systematic review with meta-analysis [J]. PLoS One. 2012, 7(12): e52182. doi:10.1371/journal.pone.0052182
|
| [17] |
Zhao W, Katzmarzyk PT, Horswell R, et al. HbA1c and coronary heart disease risk among diabetic patients [J]. Diabetes Care, 2014, 37(2): 428-35. doi:10.2337/dc13-1525
|
| [18] |
Chen J, Yin D, Dou K. Intensified glycemic control by HbA1c for patients with coronary heart disease and type 2 diabetes: a review of findings and conclusions [J]. Cardiovasc Diabetol, 2023, 22(1): 146. doi:10.1186/s12933-023-01875-8
|
| [19] |
Després JP, Lemieux I, Dagenais GR, et al. HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study [J]. Atherosclerosis, 2000, 153(2): 263-72. doi:10.1016/s0021-9150(00)00603-1
|
| [20] |
Rentsch CT, Garfield V, Mathur R, et al. Sex-specific risks for cardiovascular disease across the glycaemic spectrum: a population-based cohort study using the UK Biobank [J]. Lancet Reg Health Eur, 2023, 32: 100693. doi:10.1016/j.lanepe.2023.100693
|
| [21] |
Slomski A. High HDL cholesterol linked with death in coronary artery disease [J]. JAMA, 2022, 328(1): 10. doi:10.1001/jama.2022.10273
|
| [22] |
Liu C, Dhindsa D, Almuwaqqat Z, et al. Association between high-density lipoprotein cholesterol levels and adverse cardiovascular outcomes in high-risk populations [J]. JAMA Cardiol, 2022, 7(7): 672-80. doi:10.1001/jamacardio.2022.0912
|
| [23] |
Liu C, Dhindsa D, Almuwaqqat Z, et al. Very high high-density lipoprotein cholesterol levels and cardiovascular mortality [J]. Am J Cardiol, 2022, 167: 43-53. doi:10.1016/j.amjcard.2021.11.041
|
| [24] |
Bhatt A, Rohatgi A. HDL cholesterol efflux capacity: cardiovascular risk factor and potential therapeutic target [J]. Curr Atheroscler Rep, 2016, 18(1): 2. doi:10.1007/s11883-015-0554-1
|
| [25] |
Jordan VC. Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing [J]. J Natl Cancer Inst, 2001, 93(1): 2-4. doi:10.1093/jnci/93.1.2
|
| [26] |
Meyer MR, Barton M. Estrogens and coronary artery disease: new clinical perspectives [J]. Adv Pharmacol, 2016, 77: 307-60. doi:10.1016/bs.apha.2016.05.003
|
| [27] |
Rettberg JR, Yao J, Brinton RD. Estrogen: a master regulator of bioenergetic systems in the brain and body [J]. Front Neuroendocrinol, 2014, 35(1): 8-30. doi:10.1016/j.yfrne.2013.08.001
|
| [28] |
Gregorio KCR, Laurindo CP, Machado UF. Estrogen and glycemic homeostasis: the fundamental role of nuclear estrogen receptors ESR1/ESR2 in glucose transporter GLUT4 regulation [J]. Cells, 2021, 10(1): 99. doi:10.3390/cells10010099
|
| [29] |
Zhu D, Chung HF, Dobson AJ, et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data [J]. Lancet Public Health, 2019, 4(11): e553-64. doi:10.1016/s2468-2667(19)30155-0
|